bioAffinity Technologies
BIAFW
4 hedge funds and large institutions have $18.1K invested in bioAffinity Technologies in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 4 → 4 (0)
0.14% less ownership
Funds ownership: 8.24% → 8.1% (-0.14%)
81% less capital inflows, than outflows
Capital inflows: $130 | Capital outflows: $698
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$87 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$698 |
BIAFW Hedge Fund Activity: Q2 2026 in Review
4 of the 8,376 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q2 2026, worth a combined $18.1K — down 68% from $55.9K a quarter earlier.
Fund positioning in BIAFW was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $87. The largest seller was Citadel Advisors, cutting an estimated $698.
- 4 institutional investors held bioAffinity Technologies (BIAFW) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $18.1K of bioAffinity Technologies stock for Q2 2026, down 68% quarter-over-quarter.
- 0 funds opened new bioAffinity Technologies positions in Q2 2026 and 0 closed out.
- The largest bioAffinity Technologies buyer in Q2 2026 was UBS Group, an estimated $87 added.
- The largest bioAffinity Technologies seller in Q2 2026 was Citadel Advisors, an estimated $698 sold.
Based on aggregated 13F filings for Q2 2026.